News Channels

06 Aug 2022 U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
06 Aug 2022 Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
05 Aug 2022 Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
05 Aug 2022 Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
05 Aug 2022 Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
05 Aug 2022 Gilead Sciences to acquire MiroBio
05 Aug 2022 Amgen to acquire Chemocentryx for $4 billion in cash
04 Aug 2022 Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
04 Aug 2022 Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
04 Aug 2022 Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
04 Aug 2022 Eisai presents new findings on lecanemab's investigational subcutaneous formulation and modeling simulation of ApoE4 genotype on ARIA-E incidence at the Alzheimer's Association International Conference (AAIC) 2022
04 Aug 2022 Radiopharm enters into strategic collaboration with Lantheus and assumes PD-L1 licensing agreement from Nanomab
04 Aug 2022 Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
04 Aug 2022 ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
04 Aug 2022 OliX Pharmaceuticals Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-related Macular Degeneration
04 Aug 2022 European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
03 Aug 2022 Avenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyte™ Immunotherapy Platform
03 Aug 2022 ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
03 Aug 2022 Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors
03 Aug 2022 Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up